Magazine article Clinical Psychiatry News

Topiramate May Be Helpful Adjunct in Treatment-Resistant OCD

Magazine article Clinical Psychiatry News

Topiramate May Be Helpful Adjunct in Treatment-Resistant OCD

Article excerpt

NEW YORK -- Topiramate may be useful as an adjunct to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder, Dr. Michael Van Ameringen said in a poster presentation at the annual meeting of the American Psychiatric Association.

The researchers studied 16 consecutive obsessive-compulsive disorder (OCD) outpatients who did not respond or only partially responded to treatment for at least 14 weeks with a serotonin reuptake inhibitor such as fluoxetine (Prozac) or paroxetine (Paxil). Patients ranged in age from 18 to 65 years. Exclusion criteria were any other primary Axis I psychiatric diagnosis; a history of bipolar disorder, schizophrenia, dementia, or other cognitive disorders; initiation of psychotherapy within 4 months; or a history of kidney stones. The study was funded by Janssen-Ortho Inc., maker of topiramate (Topamax).

The investigators noted that topiramate has been shown to inhibit glutamate via alpha-AMP/kainate subreceptors. This made the drug a good subject for study, "given the recent imaging data showing an association between decreased caudate glutamatergic concentrations and a reduction in OCD symptoms," said Dr. Van Ameringen of McMaster University, Hamilton, Ont. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.